Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 8/20 | 0.75 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.65 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.65 |
| ▸ | NT5E | P21589 | 2/20 | 0.64 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.62 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.60 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.60 |
| ▸ | LDHA | P00338 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | FBP1 | P09467 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.60 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.60 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689693 | 0.95 | DNPH1 (0.71) | DNPH1P2RX3P2RX2NT5EP2RY12 | |
| SCHEMBL14689933 | 0.92 | DNPH1 (0.70) | DNPH1P2RX3P2RX2NT5EP2RY12 | |
| SCHEMBL621803 | 0.91 | DNPH1 (0.72) | DNPH1P2RX3P2RX2NT5EP2RY12 | |
| SCHEMBL14689717 | 0.91 | DNPH1 (0.69) | DNPH1P2RX3P2RX2NT5EP2RY12 | |
| SCHEMBL14689912 | 0.91 | DNPH1 (0.69) | DNPH1P2RX3P2RX2NT5EP2RY12 | |
| SCHEMBL14688927 | 0.91 | DNPH1 (0.77) | DNPH1P2RX3P2RX2NT5EP2RY12 | |
| SCHEMBL14689485 | 0.91 | DNPH1 (0.69) | DNPH1P2RX3P2RX2NT5EP2RY12 | |
| SCHEMBL14688918 | 0.91 | DNPH1 (0.71) | DNPH1P2RX3P2RX2NT5EP2RY12 | |
| SCHEMBL14689729 | 0.90 | DNPH1 (0.77) | DNPH1P2RX3P2RX2NT5EP2RY12 | |
| SCHEMBL14688777 | 0.90 | DNPH1 (0.68) | DNPH1P2RX3P2RX2NT5EP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563801-B1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5´-MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATION CONTAINING THESE COMPOUNDS | Univerzita Palackého v Olomouci (CZ) | 2014-09-24 | — | — | EP | claimed |
| US-20130040908-A1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS | BIOAPEX, S.R.O. (CZ) | 2013-02-14 | — | — | US | claimed |
| US-9073961-B2 | Substitution derivatives of N6 -benzyladenosine-5′-monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparations containing these compounds | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2015-07-07 | — | — | US | disclosed |
| EP-2563801-B1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5´-MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATION CONTAINING THESE COMPOUNDS | Univerzita Palackého v Olomouci (CZ) | 2014-09-24 | — | — | EP | disclosed |
| US-20130040908-A1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS | BIOAPEX, S.R.O. (CZ) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040908-A1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS | MTAP, RNMT, NUDT1 | DNPH1 1012/4885P2RX3 339/4885P2RX2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.